A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 23543
T-cell lymphomas (TCLs) are rare and heterogeneous tumors that can be clinically localized or systemic. Systemic TCLs are characterized by a very poor prognosis and few therapeutic options are available despite recent hopes provided by the immunotherapy and targeted therapy. TCLs are distinct from B-cell lymphomas both in their pathophysiology and epidemiology. Immunological markers and molecular techniques have shed light on the mechanisms at play in their development but there is still a gap between the large number of mutated genes identified over the last ten years and their use as targets for patient treatments. The same holds true for B-cell lymphomas for which, for twenty years, anti-CD20 (Rituximab, Mabthera) antibodies have represented a major breakthrough in their treatment. Unfortunately, there is so far no equivalent of anti-CD20 antibodies to eradicate tumor cells in TCL. The next frontier in the understanding of the pathophysiology of TCL will be crossed by the use of integrated approaches based on data hybridization. A cross correlation of data obtained from clinics, imaging, and genomics (multiomics) will further our understanding of the biological mechanisms that could be targeted in the latter tumor type.
This Special Issue will highlight recent knowledge in the biology and clinical management of TCL. Different chapters will be proposed by experts in the field worldwide. This issue is also an occasion to emphasize the wide geographical, biological and clinical diversity of these mysterious tumors that develop from cells that are at the front line of the antitumor immune response. Therefore, the search for efficient therapeutic approaches in aggressive TCL remains as a catch 22 situation for the moment.
Prof. Dr. Pierre Brousset
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- T-cell lymphoma
- gene mutations
- data mining
- targeted therapy